200 related articles for article (PubMed ID: 20609549)
1. Observational study of blue dye-assisted four-node sampling for axillary staging in early breast cancer.
Narui K; Ishikawa T; Kito A; Shimizu D; Chishima T; Momiyama N; Ichikawa Y; Sasaki T; Nozawa A; Inayama Y; Shimada H; Endo I
Eur J Surg Oncol; 2010 Aug; 36(8):731-6. PubMed ID: 20609549
[TBL] [Abstract][Full Text] [Related]
2. Blue-dye technique complements four-node sampling for early breast cancer.
Ishikawa T; Momiyama N; Hamaguchi Y; Tanabe M; Tomita S; Ichikawa Y; Nakatani Y; Sasaki T; Nozawa A; Inayama Y; Inui K; Shimada H
Eur J Surg Oncol; 2005 Dec; 31(10):1119-24. PubMed ID: 16005597
[TBL] [Abstract][Full Text] [Related]
3. Sentinel node biopsy versus low axillary sampling in women with clinically node negative operable breast cancer.
Parmar V; Hawaldar R; Nair NS; Shet T; Vanmali V; Desai S; Gupta S; Rangrajan V; Mittra I; Badwe RA
Breast; 2013 Dec; 22(6):1081-6. PubMed ID: 23948301
[TBL] [Abstract][Full Text] [Related]
4. A prospective feasibility study of sentinel node biopsy by modified Indigocarmine blue dye methods after neoadjuvant chemotherapy for breast cancer.
Kida K; Ishikawa T; Yamada A; Shimizu D; Tanabe M; Sasaki T; Ichikawa Y; Endo I
Eur J Surg Oncol; 2015 Apr; 41(4):566-70. PubMed ID: 25650249
[TBL] [Abstract][Full Text] [Related]
5. Sentinel lymph node as a new marker for therapeutic planning in breast cancer patients.
Gipponi M; Bassetti C; Canavese G; Catturich A; Di Somma C; Vecchio C; Nicolò G; Schenone F; Tomei D; Cafiero F
J Surg Oncol; 2004 Mar; 85(3):102-11. PubMed ID: 14991881
[TBL] [Abstract][Full Text] [Related]
6. The predictive value of methylene blue dye as a single technique in breast cancer sentinel node biopsy: a study from Dharmais Cancer Hospital.
Brahma B; Putri RI; Karsono R; Andinata B; Gautama W; Sari L; Haryono SJ
World J Surg Oncol; 2017 Feb; 15(1):41. PubMed ID: 28173818
[TBL] [Abstract][Full Text] [Related]
7. Blue dye versus combined blue dye-radioactive tracer technique in detection of sentinel lymph node in breast cancer.
Radovanovic Z; Golubovic A; Plzak A; Stojiljkovic B; Radovanovic D
Eur J Surg Oncol; 2004 Nov; 30(9):913-7. PubMed ID: 15498633
[TBL] [Abstract][Full Text] [Related]
8. Repeat sentinel node biopsy should be considered in patients with locally recurrent breast cancer.
Vugts G; Maaskant-Braat AJ; Voogd AC; van Riet YE; Luiten EJ; Rutgers EJ; Rutten HJ; Roumen RM; Nieuwenhuijzen GA
Breast Cancer Res Treat; 2015 Oct; 153(3):549-56. PubMed ID: 26358709
[TBL] [Abstract][Full Text] [Related]
9. [Sentinel node biopsy for breast cancer patients at the Bács-Kiskun County Teaching Hospital].
Cserni G; Rajtár M; Boross G; Sinkó M; Svébis M; Baltás B; Ambrózay E; Szúcs M
Orv Hetil; 2002 Mar; 143(9):437-46. PubMed ID: 12013684
[TBL] [Abstract][Full Text] [Related]
10. Omitting axillary lymph node dissection in sentinel node negative breast cancer patients is safe: a long term follow-up analysis.
Torrenga H; Fabry H; van der Sijp JR; van Diest PJ; Pijpers R; Meijer S
J Surg Oncol; 2004 Oct; 88(1):4-7; discussion 7-8. PubMed ID: 15384064
[TBL] [Abstract][Full Text] [Related]
11. Axillary dissection is not required for all patients with breast cancer and positive sentinel nodes.
Guenther JM; Hansen NM; DiFronzo LA; Giuliano AE; Collins JC; Grube BL; O'Connell TX
Arch Surg; 2003 Jan; 138(1):52-6. PubMed ID: 12511150
[TBL] [Abstract][Full Text] [Related]
12. Sentinel node biopsy in breast cancer has a greater node positivity rate than axillary node sample: results from a retrospective analysis.
Macaskill EJ; Dewar S; Purdie CA; Brauer K; Baker L; Brown DC
Eur J Surg Oncol; 2012 Aug; 38(8):662-9. PubMed ID: 22592099
[TBL] [Abstract][Full Text] [Related]
13. [lymphatic Mapping and Sentinel Lymph Node Biopsy in patients with Breast Cancer ].
Gallegos-Hernández JF; Chávez-García MA; Nájera I; Ramírez-Ramírez L; Durán-Martínez M
Gac Med Mex; 2003; 139(3):205-8. PubMed ID: 12872412
[TBL] [Abstract][Full Text] [Related]
14. [Exclusive use of blue dye to detect sentinel lymph nodes in breast cancer].
Bühler H S; Rojas P H; Cayazzo M D; Cunill C E; Vesperinas A G; Hamilton S J
Rev Med Chil; 2008 Aug; 136(8):1015-20. PubMed ID: 18949185
[TBL] [Abstract][Full Text] [Related]
15. Safety of sentinel node biopsy in breast cancer patients who receive a second radioisotope injection after visualization failure in lymphoscintigraphy.
Meretoja TJ; Joensuu H; Heikkilä PS; Leidenius MH
J Surg Oncol; 2010 Nov; 102(6):649-55. PubMed ID: 20976732
[TBL] [Abstract][Full Text] [Related]
16. Processing sentinel nodes in breast cancer: when and how many?
Schuman S; Walker G; Avisar E
Arch Surg; 2011 Apr; 146(4):389-93. PubMed ID: 21502448
[TBL] [Abstract][Full Text] [Related]
17. Staging and management of axillary lymph nodes in patients with local recurrence in the breast or chest wall after a previous negative sentinel node procedure.
Derkx F; Maaskant-Braat AJ; van der Sangen MJ; Nieuwenhuijzen GA; van de Poll-Franse LV; Roumen RM; Voogd AC
Eur J Surg Oncol; 2010 Jul; 36(7):646-51. PubMed ID: 20537838
[TBL] [Abstract][Full Text] [Related]
18. [Modulation of the axillary lymph node dissection in breast cancer].
Procaccini E; Ruggiero R; Mansi L; Laprovitera AP; Rambaldi PF; Cuccurullo V; Ferrara A; Procaccini F; Zenone P
Ann Ital Chir; 2003; 74(1):21-8; discussion 28-9. PubMed ID: 12870278
[TBL] [Abstract][Full Text] [Related]
19. Localization of the sentinel lymph node in breast cancer by combined lymphoscintigraphy, blue dye and intraoperative gamma probe.
Villa G; Gipponi M; Buffoni F; Vecchio C; Bianchi P; Agnese G; Di Somma C; Catturich A; Rosato F; Tomei D; Nicolò G; Badellino F; Mariani G; Canavese G
Tumori; 2000; 86(4):297-9. PubMed ID: 11016707
[TBL] [Abstract][Full Text] [Related]
20. [Usefulness of lymphatic mapping with sub-areolar injection of patent blue dye, in the typification of breast cancer].
Gallegos-Hernández JF; Chávez-García M
Rev Invest Clin; 2003; 55(4):407-11. PubMed ID: 14635604
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
